In the present study, we further found that the transcription factor SALL2 was downregulated during tamoxifen therapy via profiling of 9 paired breast cancer tissues (pre‐tamoxifen primary tumors and matched relapsed tamoxifen‐resistant tissues from the same individuals). Here, SALL2 is linked to breast carcinoma.